tiprankstipranks
Xtant Medical Holdings (XTNT)
:XTNT
US Market

Xtant Medical Holdings (XTNT) Stock Forecast & Price Target

Compare
274 Followers
See the Price Targets and Ratings of:

XTNT Financial Forecast

XTNT Earnings Forecast

Next quarter’s earnings estimate for XTNT is -$0.01 with a range of -$0.02 to >-$0.01. The previous quarter’s EPS was -$0.04. XTNT beat its EPS estimate 0.00% of the time in the past 12 months, while its overall industry beat the EPS estimate 56.98% of the time in the same period. In the last calendar year XTNT has Preformed in-line its overall industry.
Next quarter’s earnings estimate for XTNT is -$0.01 with a range of -$0.02 to >-$0.01. The previous quarter’s EPS was -$0.04. XTNT beat its EPS estimate 0.00% of the time in the past 12 months, while its overall industry beat the EPS estimate 56.98% of the time in the same period. In the last calendar year XTNT has Preformed in-line its overall industry.

XTNT Sales Forecast

Next quarter’s sales forecast for XTNT is $31.80M with a range of $31.69M to $31.90M. The previous quarter’s sales results were $27.94M. XTNT beat its sales estimates 66.67% of the time in past 12 months, while its overall industry beat sales estimates 46.49% of the time in the same period. In the last calendar year XTNT has Outperformed its overall industry.
Next quarter’s sales forecast for XTNT is $31.80M with a range of $31.69M to $31.90M. The previous quarter’s sales results were $27.94M. XTNT beat its sales estimates 66.67% of the time in past 12 months, while its overall industry beat sales estimates 46.49% of the time in the same period. In the last calendar year XTNT has Outperformed its overall industry.

Detailed List of Analyst Forecasts​

Ranks
Any
Any
Analyst Rating
Any
Any
Upside/ Downside
Any
Any
Action
Any
Any
Analyst Profile
Expert Firm
Price Target
Position
Upside / Downside
Action
Date
Follow
Article
Craig-Hallum
Buy
Reiterated
11/13/24
Craig-Hallum Reaffirms Their Buy Rating on Xtant Medical Holdings (XTNT)
BTIG
$2$3
Buy
435.71%
Upside
Reiterated
05/15/24
Analysts Have Conflicting Sentiments on These Healthcare Companies: Xtant Medical Holdings (NYSE MKT: XTNT), Teleflex (NYSE: TFX) and Esperion (NASDAQ: ESPR)
Stocks with the Highest Top Analyst Consensus in the Healthcare Sector
Find stocks in the Healthcare sector that are highly recommended by Top Performing Analysts.

Best Analysts Covering Xtant Medical Holdings

Which Analyst Should I Follow If I Want to Buy XTNT and Sell After:
1 Month
xxx
Success Rate
4/12 ratings generated profit
33%
Average Return
-1.56%
reiterated a xxx
rating 3 months ago
Copying xxxxxxxxxxxxxxxxxx
trades and holding each position for 1 Month would result in 33.33% of your transactions generating a profit, with an average return of -1.56% per trade.
3 Months
xxx
Success Rate
5/12 ratings generated profit
42%
Average Return
+2.18%
reiterated a xxx
rating 3 months ago
Copying xxxxxxxxxxxxxxxxxx
trades and holding each position for 3 Months would result in 41.67% of your transactions generating a profit, with an average return of +2.18% per trade.
1 Year
Success Rate
5/12 ratings generated profit
42%
Average Return
-10.64%
reiterated a buy rating 3 months ago
Copying Chase Knickerbocker's trades and holding each position for 1 Year would result in 41.67% of your transactions generating a profit, with an average return of -10.64% per trade.
2 Years
xxx
Success Rate
3/12 ratings generated profit
25%
Average Return
-21.68%
reiterated a xxx
rating 3 months ago
Copying xxxxxxxxxxxxxxxxxx
trades and holding each position for 2 Years would result in 25.00% of your transactions generating a profit, with an average return of -21.68% per trade.
The Best Analyst Covering tool allows you to follow the analysts who have the best success rates and average returns on a specific stock. Only analysts that gave a Buy or Sell rating on the stock in the past 12 months are eligible for inclusion in this tool. Follow the analysts of your choice to receive real-time updates when they publish a new rating.

XTNT Analyst Recommendation Trends

Rating
May 24
Aug 24
Sep 24
Oct 24
Nov 24
Strong Buy
3
3
2
1
1
Buy
4
4
3
3
2
Hold
0
0
0
0
0
Sell
0
0
0
0
0
Strong Sell
0
0
0
0
0
total
7
7
5
4
3
In the current month, XTNT has received 3 Buy Ratings, 0 Hold Ratings, and 0 Sell Ratings. XTNT average Analyst price target in the past 3 months is .
Each month's total comprises the sum of three months' worth of ratings.

XTNT Stock Forecast FAQ

What is XTNT’s average 12-month price target, according to analysts?
Currently, no data Available
What is XTNT’s upside potential, based on the analysts’ average price target?
Currently there's no upside potential for XTNT, based on the analysts’ average price target.
Can I see which stocks the top-ranking analysts are rating?
Yes, go to the Analysts’ Top Stocks tool to see stocks with a Strong Buy or Strong Sell analyst rating consensus, according to the top performers.
    How can I follow the stock ratings of top Wall Street analysts?
    Head over to our Expert Center to see a list of the top 100 Wall Street analysts and follow the analysts of your choice. Visit their profiles for more details about their stock ratings and see how they perform on a stock-by-stock basis.
      Is XTNT a Buy, Sell or Hold?
      Xtant Medical Holdings has a consensus rating of Moderate Buy which is based on 0 buy ratings, 0 hold ratings and 0 sell ratings.
        What is Xtant Medical Holdings’s price target?
        Currently, no data Available
        What do analysts say about Xtant Medical Holdings?
        Xtant Medical Holdings’s analyst rating consensus is a Moderate Buy. This is based on the ratings of 0 Wall Streets Analysts.
          How can I buy shares of XTNT?
          Open a brokerage account, see exclusive account opening deals on our Best Online Brokers page.
            What am I Missing?
            Make informed decisions based on Top Analysts' activity
            Know what industry insiders are buying
            Get actionable alerts from top Wall Street Analysts
            Find out before anyone else which stock is going to shoot up
            Get powerful stock screeners & detailed portfolio analysis